39.44 USD
-0.28 (-0.7%)
39.44 USD
0 (0%)
Overall PAHC gets a fundamental rating of 7 out of 10. We evaluated PAHC against 192 industry peers in the Pharmaceuticals industry. While PAHC belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. PAHC scores decently on growth, while it is valued quite cheap. This could make an interesting combination. Finally PAHC also has an excellent dividend rating. This makes PAHC very considerable for value and dividend investing!
1. Profitability
1.1 Basic Checks
In the past year PAHC was profitable.
In the past year PAHC had a positive cash flow from operations.
In the past 5 years PAHC has always been profitable.
In the past 5 years PAHC always reported a positive cash flow from operatings.
1.2 Ratios
PAHC has a Return On Assets of 4.89%. This is amongst the best in the industry. PAHC outperforms 86.39% of its industry peers.
PAHC's Return On Equity of 21.76% is amongst the best of the industry. PAHC outperforms 92.15% of its industry peers.
PAHC has a Return On Invested Capital of 11.94%. This is amongst the best in the industry. PAHC outperforms 91.10% of its industry peers.
The Average Return On Invested Capital over the past 3 years for PAHC is below the industry average of 12.85%.
The last Return On Invested Capital (11.94%) for PAHC is above the 3 year average (8.29%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.89% | ||
| ROE | 21.76% | ||
| ROIC | 11.94% |
ROA(3y)2.38%
ROA(5y)3.78%
ROE(3y)9.79%
ROE(5y)14.19%
ROIC(3y)8.29%
ROIC(5y)8.41%
1.3 Margins
The Profit Margin of PAHC (4.85%) is better than 81.68% of its industry peers.
PAHC's Profit Margin has declined in the last couple of years.
PAHC has a better Operating Margin (12.04%) than 84.82% of its industry peers.
In the last couple of years the Operating Margin of PAHC has grown nicely.
PAHC has a Gross Margin (31.92%) which is in line with its industry peers.
PAHC's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.04% | ||
| PM (TTM) | 4.85% | ||
| GM | 31.92% |
OM growth 3Y8.12%
OM growth 5Y4.74%
PM growth 3Y-10.66%
PM growth 5Y-2.37%
GM growth 3Y1.41%
GM growth 5Y-0.32%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PAHC is creating some value.
The number of shares outstanding for PAHC remains at a similar level compared to 1 year ago.
Compared to 5 years ago, PAHC has about the same amount of shares outstanding.
PAHC has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.10 indicates that PAHC is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.10, PAHC is doing good in the industry, outperforming 65.44% of the companies in the same industry.
The Debt to FCF ratio of PAHC is 21.67, which is on the high side as it means it would take PAHC, 21.67 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 21.67, PAHC is in the better half of the industry, outperforming 75.39% of the companies in the same industry.
A Debt/Equity ratio of 2.32 is on the high side and indicates that PAHC has dependencies on debt financing.
The Debt to Equity ratio of PAHC (2.32) is worse than 79.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.32 | ||
| Debt/FCF | 21.67 | ||
| Altman-Z | 3.1 |
ROIC/WACC1.3
WACC9.15%
2.3 Liquidity
A Current Ratio of 3.09 indicates that PAHC has no problem at all paying its short term obligations.
The Current ratio of PAHC (3.09) is comparable to the rest of the industry.
A Quick Ratio of 1.35 indicates that PAHC should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.35, PAHC is doing worse than 68.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.09 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
PAHC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.43%, which is quite impressive.
Measured over the past years, PAHC shows a quite strong growth in Earnings Per Share. The EPS has been growing by 14.12% on average per year.
PAHC shows a strong growth in Revenue. In the last year, the Revenue has grown by 33.71%.
Measured over the past years, PAHC shows a quite strong growth in Revenue. The Revenue has been growing by 10.12% on average per year.
EPS 1Y (TTM)76.43%
EPS 3Y19.98%
EPS 5Y14.12%
EPS Q2Q%108.57%
Revenue 1Y (TTM)33.71%
Revenue growth 3Y11.21%
Revenue growth 5Y10.12%
Sales Q2Q%39.74%
3.2 Future
The Earnings Per Share is expected to grow by 17.77% on average over the next years. This is quite good.
The Revenue is expected to decrease by -2.45% on average over the next years.
EPS Next Y33.72%
EPS Next 2Y21.35%
EPS Next 3Y17.77%
EPS Next 5YN/A
Revenue Next Year14.65%
Revenue Next 2Y8.81%
Revenue Next 3Y6.86%
Revenue Next 5Y-2.45%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
PAHC is valuated correctly with a Price/Earnings ratio of 15.97.
PAHC's Price/Earnings ratio is rather cheap when compared to the industry. PAHC is cheaper than 84.82% of the companies in the same industry.
PAHC's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.19.
The Price/Forward Earnings ratio is 12.81, which indicates a correct valuation of PAHC.
Based on the Price/Forward Earnings ratio, PAHC is valued cheaper than 84.29% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.88. PAHC is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.97 | ||
| Fwd PE | 12.81 |
4.2 Price Multiples
PAHC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PAHC is cheaper than 89.01% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, PAHC is valued a bit cheaper than 78.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 46.62 | ||
| EV/EBITDA | 10.35 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of PAHC may justify a higher PE ratio.
A more expensive valuation may be justified as PAHC's earnings are expected to grow with 17.77% in the coming years.
PEG (NY)0.47
PEG (5Y)1.13
EPS Next 2Y21.35%
EPS Next 3Y17.77%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.21%, PAHC has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 0.35, PAHC pays a better dividend. On top of this PAHC pays more dividend than 91.10% of the companies listed in the same industry.
Compared to the average S&P500 Dividend Yield of 1.90, PAHC is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.21% |
5.2 History
The dividend of PAHC has a limited annual growth rate of 0.02%.
PAHC has paid a dividend for at least 10 years, which is a reliable track record.
PAHC has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)0.02%
Div Incr Years0
Div Non Decr Years10
5.3 Sustainability
28.68% of the earnings are spent on dividend by PAHC. This is a low number and sustainable payout ratio.
PAHC's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP28.68%
EPS Next 2Y21.35%
EPS Next 3Y17.77%
39.44
-0.28 (-0.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners100.08%
Inst Owner Change0%
Ins Owners0.52%
Ins Owner Change31.32%
Market Cap1.60B
Revenue(TTM)1.40B
Net Income(TTM)67.82M
Analysts48.89
Price Target43.86 (11.21%)
Short Float %4.47%
Short Ratio2.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.21% |
Yearly Dividend0.48
Dividend Growth(5Y)0.02%
DP28.68%
Div Incr Years0
Div Non Decr Years10
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.22%
Min EPS beat(2)7.47%
Max EPS beat(2)14.97%
EPS beat(4)4
Avg EPS beat(4)16.45%
Min EPS beat(4)7.47%
Max EPS beat(4)24.57%
EPS beat(8)8
Avg EPS beat(8)18.22%
EPS beat(12)9
Avg EPS beat(12)8.1%
EPS beat(16)10
Avg EPS beat(16)2.75%
Revenue beat(2)2
Avg Revenue beat(2)2.66%
Min Revenue beat(2)2.5%
Max Revenue beat(2)2.82%
Revenue beat(4)2
Avg Revenue beat(4)0.47%
Min Revenue beat(4)-3.24%
Max Revenue beat(4)2.82%
Revenue beat(8)6
Avg Revenue beat(8)1.31%
Revenue beat(12)6
Avg Revenue beat(12)-0.12%
Revenue beat(16)10
Avg Revenue beat(16)0.58%
PT rev (1m)0%
PT rev (3m)31.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.47%
EPS NY rev (1m)0%
EPS NY rev (3m)4.08%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.97 | ||
| Fwd PE | 12.81 | ||
| P/S | 1.14 | ||
| P/FCF | 46.62 | ||
| P/OCF | 20.81 | ||
| P/B | 5.13 | ||
| P/tB | 7.37 | ||
| EV/EBITDA | 10.35 |
EPS(TTM)2.47
EY6.26%
EPS(NY)3.08
Fwd EY7.8%
FCF(TTM)0.85
FCFY2.15%
OCF(TTM)1.89
OCFY4.8%
SpS34.53
BVpS7.69
TBVpS5.35
PEG (NY)0.47
PEG (5Y)1.13
Graham Number20.67
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.89% | ||
| ROE | 21.76% | ||
| ROCE | 15.11% | ||
| ROIC | 11.94% | ||
| ROICexc | 12.92% | ||
| ROICexgc | 14.23% | ||
| OM | 12.04% | ||
| PM (TTM) | 4.85% | ||
| GM | 31.92% | ||
| FCFM | 2.45% |
ROA(3y)2.38%
ROA(5y)3.78%
ROE(3y)9.79%
ROE(5y)14.19%
ROIC(3y)8.29%
ROIC(5y)8.41%
ROICexc(3y)9.26%
ROICexc(5y)9.5%
ROICexgc(3y)10.65%
ROICexgc(5y)11.26%
ROCE(3y)10.49%
ROCE(5y)10.64%
ROICexgc growth 3Y1.17%
ROICexgc growth 5Y-1.23%
ROICexc growth 3Y4.48%
ROICexc growth 5Y1.99%
OM growth 3Y8.12%
OM growth 5Y4.74%
PM growth 3Y-10.66%
PM growth 5Y-2.37%
GM growth 3Y1.41%
GM growth 5Y-0.32%
F-Score5
Asset Turnover1.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.32 | ||
| Debt/FCF | 21.67 | ||
| Debt/EBITDA | 3.32 | ||
| Cap/Depr | 86.01% | ||
| Cap/Sales | 3.04% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 35.24% | ||
| Profit Quality | 50.56% | ||
| Current Ratio | 3.09 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 3.1 |
F-Score5
WACC9.15%
ROIC/WACC1.3
Cap/Depr(3y)116.74%
Cap/Depr(5y)111.08%
Cap/Sales(3y)4.1%
Cap/Sales(5y)3.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.43%
EPS 3Y19.98%
EPS 5Y14.12%
EPS Q2Q%108.57%
EPS Next Y33.72%
EPS Next 2Y21.35%
EPS Next 3Y17.77%
EPS Next 5YN/A
Revenue 1Y (TTM)33.71%
Revenue growth 3Y11.21%
Revenue growth 5Y10.12%
Sales Q2Q%39.74%
Revenue Next Year14.65%
Revenue Next 2Y8.81%
Revenue Next 3Y6.86%
Revenue Next 5Y-2.45%
EBIT growth 1Y95.15%
EBIT growth 3Y20.25%
EBIT growth 5Y15.34%
EBIT Next Year75.33%
EBIT Next 3Y25.44%
EBIT Next 5Y2.18%
FCF growth 1Y732.23%
FCF growth 3YN/A
FCF growth 5Y10.58%
OCF growth 1Y91.01%
OCF growth 3Y36.29%
OCF growth 5Y6.19%
PHIBRO ANIMAL HEALTH CORP-A / PAHC FAQ
Can you provide the ChartMill fundamental rating for PHIBRO ANIMAL HEALTH CORP-A?
ChartMill assigns a fundamental rating of 7 / 10 to PAHC.
What is the valuation status of PHIBRO ANIMAL HEALTH CORP-A (PAHC) stock?
ChartMill assigns a valuation rating of 7 / 10 to PHIBRO ANIMAL HEALTH CORP-A (PAHC). This can be considered as Undervalued.
Can you provide the profitability details for PHIBRO ANIMAL HEALTH CORP-A?
PHIBRO ANIMAL HEALTH CORP-A (PAHC) has a profitability rating of 8 / 10.
What is the financial health of PHIBRO ANIMAL HEALTH CORP-A (PAHC) stock?
The financial health rating of PHIBRO ANIMAL HEALTH CORP-A (PAHC) is 5 / 10.
What is the expected EPS growth for PHIBRO ANIMAL HEALTH CORP-A (PAHC) stock?
The Earnings per Share (EPS) of PHIBRO ANIMAL HEALTH CORP-A (PAHC) is expected to grow by 33.72% in the next year.